LONDON & NEW YORK, March 18, 2025--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced the ...

The results of COMP004 build upon previous findings from the Phase 2b trial COMP001, which showed that a single 25mg dose of COMP360 psilocybin was associated with a rapid and highly statistically ...

In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic stocks. The Therapeutic Potential and Investment Boom in Psychedelic ...

COMPASS Pathways plc (NASDAQ:CMPS – Get Free Report) has been given an average rating of “Buy” by the seven ratings firms ...

In this article, we are going to take a look at where COMPASS Pathways plc (NASDAQ:CMPS) stands against the other psychedelic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

1 Day CMPS -4.97% DJIA 0.92% Russell 2K 1.57% Health Care/Life Sciences 0.19% ...

Ladies and gentlemen, thank you for standing by, and welcome to the COMPASS Pathways Limited fourth quarter 2024 investor call. [Operator instructions] I will now hand today's call over to Steve ...